✦ LIBER ✦

Human pharmacokinetics and modeling of the concentration-attenuation relationship of a new liposomal liver-specific contrast agent for CT

✍ Scribed by Höglund, Peter; Leander, Peter; Hustvedt, Svein Olav; Kloster, Yngvil; Børseth, Arve

Book ID: 122458582
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 160 KB
Volume: 5
Category: Article
ISSN: 1076-6332
DOI: 10.1016/S1076-6332(98)80056-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A new liposomal liver-specific contrast

A new liposomal liver-specific contrast agent for CT: first human phase-I clinical trial assessing efficacy and safety

✍ P. Leander; Peter Höglund; Arve Børseth; Yngvil Kloster; Arne Berg 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 133 KB

Biliary excretion and pharmacokinetics o

Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat

✍ Gabriele Schuhmann-Giampieri; Heribert Schitt-Willich; Thomas Frenzel 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 735 KB

The introduction of a lipophilic moiety into the gadolinium chelate Gd-DTPA (dimeglumine gadopentetate, Magnevist) yielded Gd-EOB-DTPA (short form), which has potential as a magnetic resonance contrast agent for liver mass screening. The pharmacokinetics of Gd-EOB-DTPA in rats is nonlinear because a

Ferucarbotran (Resovist): a new clinical

Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications

✍ Peter Reimer,Thomas Balzer 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 742 KB

A new model for embryotoxicity testing:

A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations

✍ H. Nau; R. Zierer; H. Spielmann; D. Neubert; Ch. Gansau 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 542 KB